Related Experiment Video

Updated: Jun 30, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

85

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Michael Wysota1, Marina Konopleva2, Shane Mitchell3

  • 1Department of Oncology, Montefiore Medical Center, 111 East 210 Street, Bronx, NY, 10467, USA. mwysota@montefiore.org.

Current Oncology Reports
|March 19, 2024
PubMed
Abstract

Insights

Novel targeted therapies are improving outcomes for acute myeloid leukemia (AML) patients. This review details new genetic and protein targets and their associated treatments for AML.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) remains a significant challenge, with high mortality rates, especially in elderly or relapsed/refractory patients.
  • Recent advancements in understanding AML's molecular and genetic drivers have paved the way for targeted therapeutic strategies.
  • Despite slow historical improvements, recent breakthroughs offer renewed hope for better patient outcomes.

Purpose of the Study:

  • To identify and describe novel genetic and protein targets in acute myeloid leukemia (AML).
  • To review associated therapeutics currently in use or under investigation for AML treatment.
  • To highlight advancements in targeted therapy for AML.

Main Methods:

  • Literature review of recent scientific publications and clinical trial data.
  • Analysis of FDA-approved targeted therapies for AML.
  • Identification of emerging therapeutic targets and agents in preclinical and clinical development.

Main Results:

  • Several targeted therapies have been FDA-approved in the last 5-6 years for newly diagnosed and relapsed/refractory AML.
  • These novel therapeutics, along with ongoing investigational agents, demonstrate significant activity against AML.
  • The identification of specific molecular drivers has led to the development of effective targeted treatments.

Conclusions:

  • Targeted therapies leveraging identified molecular/genetic drivers are significantly improving outcomes for AML patients.
  • Continued research into novel targets and therapeutics is crucial for further enhancing AML treatment efficacy.
  • These advancements offer substantial improvements in survival and quality of life for a growing number of AML patients.
Keywords:
AMLAcute myeloid leukemiaImmune therapyMolecular targetsNovel therapeutics

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K